Drug Profile


Alternative Names: PRCL02

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PRCL Research Inc
  • Class Antipsoriatics
  • Mechanism of Action ORAI1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 03 Aug 2018 PRCL Research plans a phase II trial for Plaque Psoriasis in August 2018 , (NCT03614078)
  • 08 Feb 2018 PRCL Research completes a phase I trial in Plaque psoriasis in Canada (NCT03062618)
  • 20 Feb 2017 Phase-I clinical trials in Plaque psoriasis in Canada (PO) (NCT03062618)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top